Optimizette

Quick links to important sections

Optimizette

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Optimizette

What is Optimizette? (Desogestrel)

Property Description
Active ingredient Desogestrel (Prodrug for Etonogestrel)
Form Film-coated oral tablet
Pharmacological class Hormonal Contraceptive / Progestin
Common use Prevention of pregnancy
Origin Synthetic (Third-generation progestogen)

Optimizette is a prescription-only hormonal contraceptive medicine classified as a Progestogen-Only Pill (POP), often generically known as the mini pill. Its sole purpose is the prevention of pregnancy. Unlike many other formulations, Optimizette is a single-component product that contains only the synthetic hormone Desogestrel and no estrogen. This estrogen-free profile is a differentiating factor, making it an important choice for women who have specific medical contraindications or preferences against estrogen-containing drugs.

Composition and Classification of Desogestrel

The active ingredient, Desogestrel (INN), is a third-generation progestogen and progestin, chemically belonging to the gonane family of synthetic compounds. Desogestrel is functionally an inactive prodrug, meaning it requires metabolism in the body to convert into its highly active form, etonogestrel (or 3-ketodesogestrel). Pharmacological data indicates that etonogestrel combines high progestational activity with minimal intrinsic androgenic activity. This unique molecular profile is why Desogestrel is considered a potent progestin for contraceptive use.

General Contraceptive Principle

Optimizette’s efficacy is primarily achieved through the systemic inhibition of ovulation, effectively stopping the monthly release of an egg from the ovary, a characteristic associated with Desogestrel-type POPs. This mechanism is noted for providing a different contraceptive profile than older POP formulations. The medication is further supported by a secondary action: increasing the viscosity of the cervical mucus to create a physical barrier against sperm entry, thereby ensuring comprehensive pregnancy prevention.

Regulatory References

  1. Efficacy of Progestin-Only Pills

What side effects are possible with Optimizette?

Possible Side Effects and Safety Information

The official safety information for Optimizette (desogestrel) outlines adverse reactions grouped by frequency and the organ systems affected. These classifications ensure a neutral communication of risks based on observed clinical trial data.

Frequency-Classified Adverse Reactions

The following effects are organized according to regulatory frequency standards:

Classification Examples of Reactions
Common (ge 1/100 to < 1/10) Irregular menstruation, headache, mood changes, breast pain, nausea, weight increased, acne.
Uncommon (ge 1/1,000 to < 1/100) Vaginal infection, contact lens intolerance, vomiting, ovarian cyst, fatigue, hair loss (alopecia).
Rare (ge 1/10,000 to < 1/1,000) Specific skin reactions such as rash, urticaria (hives), and erythema nodosum.

Adverse reactions are further categorized into System-Organ Classes (SOCs), which include Reproductive System and Breast Disorders, Nervous System Disorders, Gastrointestinal Disorders, and Skin and Subcutaneous Tissue Disorders.

Serious Safety Considerations

Official labels detail serious safety risks that require specific caution. The presence of an active Venous Thromboembolic Disorder (VTE) is a contraindication, and the possibility of VTE developing requires cessation of use. The medication is also contraindicated in individuals with a history of severe hepatic disease or sex-steroid sensitive malignancies. Ectopic pregnancy is noted as a possibility that must be considered if a patient experiences amenorrhoea or abdominal pain.

Time-Related and Population Safety Notes

Certain effects are tied to the duration of exposure; for instance, vaginal bleeding disturbances (spotting, breakthrough bleeding) are commonly noted to occur during the first 3 months of initial use. Regarding specific populations, the medicine is noted to be acceptable for use during breast-feeding with careful observation, but it is strictly contraindicated in cases of undiagnosed vaginal bleeding.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for an overdose of Optimizette (Desogestrel) is defined by the absence of reported severe outcomes. Regulatory documentation explicitly states that no serious harmful effects have been reported following the ingestion of multiple tablets. This low-risk classification is consistent across authorized prescribing information.

The documented clinical presentation of an overdose is limited to mild and transient effects, primarily affecting the gastrointestinal and reproductive systems. The specific manifestations listed in regulatory sources include nausea and vomiting. A specific finding noted in the official labeling is the occurrence of slight vaginal bleeding in young girls (prepubescent females).

In the event of an overdose, the required emergency action is to seek medical attention for symptomatic and supportive management. The regulatory profile dictates that since no specific antidote is known or available, clinical management is focused entirely on treating the documented symptoms. Urgent medical attention should be sought if any of the documented manifestations persist, become severe, or require professional clinical evaluation to ensure symptomatic recovery. This approach reflects the officially documented low severity of the overdose profile.

Therapeutic Uses of Optimizette

What Optimizette treats: Main Uses and Benefits

Optimizette's foremost use is providing effective contraception to manage the risk of unintended conception. This medication is commonly used for its action in managing the risk of conception. This action is applied across domains where additional symptomatic support is needed. The medication is relevant across three main therapeutic areas: contraception, management of excessive menstrual bleeding, and management of severe menstrual cramping. It supports the patient during the episode of pregnancy risk and assists with maintaining functional stability.

The medication is also generally relevant in conditions involving episodic or fluctuating manifestations, such as adverse menstrual cycle patterns. This assists with maintaining functional stability during the menstrual cycle. This includes women who are currently breastfeeding or those with established estrogen sensitivities, and may be part of symptomatic management.


Quick Fact: Management of Symptoms Related to Physical Discomfort

The medication is commonly used to help with symptoms related to physical discomfort, such as menorrhagia (excessive blood loss) and dysmenorrhea (severe menstrual cramping).

Eligibility and Restrictions for Use

Who Can and Cannot Use Optimizette?

Optimizette (desogestrel) eligibility is strictly defined by regulatory authorities and centers on specific medical conditions, organ function, and life stages. This medication is generally intended for women of childbearing potential who require contraception, including those who may have a contraindication to estrogen-containing pills.

Absolute Non-Eligibility (Contraindications)

Individuals must not use Optimizette if they have an active venous thromboembolic disorder (such as deep vein thrombosis or pulmonary embolism). It is also contraindicated for patients with a history of severe hepatic disease until liver function has fully normalized, or those with known or suspected sex-steroid sensitive malignancies, particularly breast cancer.

Conditional and Age-Related Use

Use is contraindicated during a known or suspected pregnancy. However, the medicine may be used during breastfeeding (lactation). Regulatory data state that safety and efficacy in adolescents below 18 years has not been established due to a lack of available clinical data. Discontinuation should be considered if sustained hypertension develops that is unresponsive to therapy.

What should I know about interactions with other medicines?

Optimizette (Desogestrel) exhibits officially documented pharmacokinetic interactions, primarily concerning substances that alter the plasma concentration of its active metabolite, etonogestrel.

Contraindicated Drug Combinations

Co-administration with specific antiviral regimens, such as the combination of ombitasvir/paritaprevir/ritonavir, with or without dasabuvir, is classified as strictly contraindicated. This restriction is based on the documented risk of severe outcomes, including increasing liver enzyme levels (ALT elevation), when combined with hormonal contraceptives.

Interactions Reducing Hormone Exposure

Several medicinal products are officially documented to reduce the level of etonogestrel in the body by accelerating its clearance. This includes potent enzyme-inducing drugs like the anti-epileptics carbamazepine, phenytoin, and barbiturates, as well as the antibiotic rifampicin. This reduction in exposure is a significant pharmacokinetic concern noted in regulatory labeling. Additionally, the herbal product Hypericum perforatum (St John's Wort) is officially recognized as an enzyme inducer that may also reduce hormone levels.

Timing Requirements and Other Interactions

Following the discontinuation of any potent enzyme-inducing drug, regulatory labels state a mandatory timing rule: alternative or non-hormonal contraception must be used for 28 days to ensure reliable hormone levels. Separately, the co-administration of berotralstat is documented to increase the exposure to etonogestrel. The interaction profile is complex and is primarily defined by these effects on metabolism.

Mechanism of Action

How Optimizette Works

Optimizette is an oral progestin-only medication containing desogestrel, which is rapidly converted to the active metabolite, etonogestrel. The mechanism of action is mediated through three principal pharmacodynamic domains.

Etonogestrel acts as an agonist at progesterone receptors, primarily exerting an antigonadotropic effect on the hypothalamic-pituitary-ovarian (HPO) axis. This interaction suppresses the pulsatile release of Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH) from the anterior pituitary gland. The resulting upstream physiological consequence is the inhibition of follicular maturation and ovulation.

Simultaneously, the drug modulates signaling sequences in the cervical epithelium. This localized activity causes a significant increase in the viscosity and density of the cervical mucus, creating a biophysical barrier that impedes sperm transport into the upper reproductive tract. Additionally, etonogestrel induces changes in the uterine lining, leading to endometrial thinning and a consequential reduction in endometrial receptivity to implantation.

Dosage and Administration Information

How Optimizette is Used

Optimizette is administered by the oral route as a film-coated tablet containing the single active dose of 0.075 mg desogestrel. The medication is designed for continuous, long-term use, without a scheduled interruption.

Standard Dosing Regimen

The standard adult dosing regimen is one tablet once daily. The administration must occur at the same time every day to ensure the interval between two tablets is consistently 24 hours. The tablet can be taken with or without food, as this is not specified as a procedural constraint.

Administration Scope Guideline
Route of Administration Oral; tablet swallowed whole.
Dosing Schedule One 0.075 mg tablet taken daily.
Cycle Pattern Continuous 28-day cycle with no break between packs.

Constraints and Procedural Rules

Optimizette is structured as a continuous 28-tablet pack regimen. When one pack is completed, a new one must be started immediately on the following day. This practice ensures uninterrupted drug concentration, which is critical for the continuous-use progestogen-only pill type.

The medication's administration is strictly time-dependent. If the scheduled tablet is taken more than 12 hours late, this is a procedural lapse that requires specific protocol. Furthermore, this medicine may be used during specific periods, such as while breastfeeding, which is a recognized usage.

Recent Clinical Evidence

Optimizette: Recent Clinical Evidence

The clinical evaluation for Optimizette (Desogestrel POP) is primarily grounded in Randomized Controlled Trials (RCTs) and large-scale studies reviewed by regulators. These studies focused on measuring pregnancy risk using the Pearl Index, which reflects the number of observed pregnancies per 100 women over a year. Researchers also monitored physiological markers, such as the rate of ovulation, by tracking follicular activity in participants. Research examined this formulation against older Progestogen-Only Pills (POPs) in comparative trials. The evidence indicates that the reported Pearl Index measurements reflect the findings for the populations observed in the clinical trial settings.

Evidence has also explored the medicine’s use in specific contexts. Studies monitored menstrual pattern regulation, tracking the incidence of amenorrhea (absence of bleeding), prolonged bleeding, and spotting over defined timeframes. Studies reported that a substantial number of women experienced changes in their bleeding pattern, with irregular bleeding being reported as a reason for discontinuation in clinical trials. Research has also been conducted for postpartum and breastfeeding women, where studies monitored the risk of pregnancy and assessed infant health outcomes, such as growth parameters, and reported that milk volume and nutrient levels were observed to be similar between groups and non-users.

Regarding the scope of the evidence, key regulatory trials typically monitored subjects for contraceptive outcomes over a minimum duration of 12 months. Data exploring effects beyond two to three years of continuous use are not fully established. There is also limited information for specific long-term outcomes in groups with certain complex chronic conditions. Furthermore, comprehensive comparative evidence is lacking between this specific Desogestrel POP and all other newly available hormonal contraceptives.

Key Studies & References

  1. Progestogen-only pills for contraception (Cochrane Review)
  2. Progestogen-only contraceptive use during breastfeeding: an updated systematic review
  3. Desogestrel 75 microgram film-coated tablets (Summary of Product Characteristics/SPC)

Frequently Asked Questions (FAQ)

Common questions about Optimizette (FAQ)

Q: How quickly does Optimizette start working?

Official product information describes that if tablet-taking starts on the first day of the menstrual cycle, contraceptive protection begins immediately. If starting on days 2 to 5 of the menstrual cycle, regulatory guidance includes the recommendation to use an additional barrier method for the first 7 days of use.

Q: What happens if I miss taking Optimizette at the usual time?

Regulatory instructions state that if a tablet is missed by less than 12 hours, the missed tablet should be taken immediately and the next one taken at the usual time. If the delay is more than 12 hours, an additional barrier method is advised for the next 7 days, and the possibility of pregnancy should be considered, particularly if tablets were missed in the first week.

Q: Does Optimizette cause weight gain, based on research?

Based on observed clinical trial data, weight increased is listed in official documents as a Common side effect. This classification indicates it was reported by between 1 in 10 and 1 in 100 people using the medicine.

Q: Does Optimizette stop the menstrual period entirely for some users?

Yes, official safety labels note that bleeding patterns may change while taking this medicine. These disturbances can include the absence of bleeding, known as amenorrhea. If bleeding stops and tablets were not taken correctly, regulatory instructions state that the possibility of pregnancy should be considered.

Q: What kind of digestive issues might be linked to Optimizette use?

Official product information lists nausea as a Common adverse reaction and vomiting as an Uncommon adverse reaction. These classifications reflect the frequency reported during clinical trials.

Q: Can I still get pregnant if I have diarrhea or vomiting while on Optimizette?

Regulatory labels state that if severe gastro-intestinal disturbance (such as vomiting within 3-4 hours of taking the tablet or severe diarrhea) occurs, the absorption of the hormone may be incomplete. In such events, the official guidance refers users to the advice for missed tablets, noting that additional contraceptive measures may be required.

Q: What are the known drug interactions between Optimizette and antibiotics?

The official product information mentions that the antibiotic rifampicin is a potent enzyme-inducing drug that can reduce the level of the active hormone, requiring extra precautions. However, non-enzyme-inducing antibiotics are generally not listed as interacting in the same way.

Q: How long do side effects typically last after starting Optimizette?

Regulatory documents describe that vaginal bleeding disturbances (such as spotting) are commonly noted to occur during the first 3 months of initial use as your body adjusts. The duration of other common side effects, like headaches or mood changes, is not specifically defined in the core regulatory information.

Q: What is the difference between Optimizette and other desogestrel-only pills?

Optimizette is simply one of the brand names for the generic active ingredient desogestrel 0.075 mg. Other brands containing only desogestrel 0.075 mg share the exact same active ingredient and official mechanism of action described in regulatory documents.

Q: Do studies suggest Optimizette has any effect on bone density?

Studies on hormonal contraception and bone mineral density have been conducted. Findings from one study comparing desogestrel pills to non-users suggested that changes in bone mineral density were not significantly different between the two groups over the period of the study.

Q: What type of headaches are associated with taking Optimizette?

Official product information lists headache as a Common adverse reaction. However, the regulatory documents do not typically distinguish or classify the specific types of headache (such as tension or migraine) that may be experienced in the frequency-classified list.

Q: What happens to my fertility after I stop taking Optimizette?

Public health documents state that fertility generally returns to its natural rhythm shortly after stopping the progestogen-only pill. The medicine is generally not associated with long-term changes in fertility beyond the time of use.

Q: Is there a link between Optimizette and hair loss or changes?

Yes, official safety labels list hair loss (alopecia) as an Uncommon adverse reaction, meaning it was reported by between 1 in 1,000 and 1 in 100 people during clinical trials.

Q: Do food or supplements interact with Optimizette?

The official product information specifically notes that the herbal product St John’s Wort (Hypericum perforatum) can reduce hormone levels and should be avoided. Generally, no interactions are listed for common foods or non-herbal nutritional supplements in the core regulatory product documents.

Q: What is the general success rate described in official studies for Optimizette?

Clinical studies reviewed by regulators for this formulation report a Pearl Index (a measurement of pregnancies per 100 women using the method for a year) as low as 0.04 in large-scale efficacy studies. Reported indices are noted to reflect the study conditions and may vary in general use.

Q: Does Optimizette affect the results of common blood tests?

Regulatory documents for hormonal contraceptives generally note that their use can influence the results of some laboratory tests. These include tests assessing liver, thyroid, adrenal, and renal function, as well as tests related to binding protein levels.

Q: Are vision changes ever listed as a side effect of Optimizette?

The official labels list contact lens intolerance as an Uncommon adverse reaction. However, a change in vision or visual disturbances is not separately or explicitly listed as a classified adverse reaction in the product information.

Q: What does the research suggest about mood changes vs. combined pills?

Official regulatory reviews of desogestrel Progestogen-Only Pill (POP) efficacy primarily focus on comparing it to older POP formulations for contraceptive outcomes. Comprehensive comparative evidence against all types of combined hormonal contraceptives is generally lacking or limited in the core product information.

Q: Can Optimizette be used to help manage symptoms of PCOS?

The sole therapeutic indication officially listed for Optimizette in regulatory documents is oral contraception (prevention of pregnancy). This means the medicine is not officially indicated or approved for other conditions like managing the symptoms of Polycystic Ovary Syndrome (PCOS).

Q: Are there specific times of day that are better for taking Optimizette?

Official instructions specify only that the tablet must be taken at the same time every day to ensure a consistent 24-hour interval between doses. No guidance is provided on whether a specific time of day (such as morning or evening) is superior for patient compliance or tolerability.

How should Optimizette be stored and disposed of?

How to Store and Dispose of Optimizette

Official regulatory documents define specific requirements for the storage and disposal of Optimizette (desogestrel 75 microgram tablets) to ensure product stability and safety.

Storage Requirements

Optimizette does not require any special temperature storage conditions. The tablets must be protected from environmental factors by storing the blister pack in the original sachet in order to protect from light and moisture.

Storage Constraint Requirement
Temperature No special conditions required
Container Store in original sachet
Stability Use within one month of first opening the sachet
Safety Keep out of the sight and reach of children

Disposal Instructions

Unused or expired Optimizette must be disposed of according to local requirements. The medicine must not be thrown into household waste or wastewater, as the active substance poses an established environmental risk to aquatic organisms.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Optimizette found in:

A-Z Index: